|
US7989465B2
(en)
*
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
TWI552752B
(zh)
|
2007-10-19 |
2016-10-11 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
MX353308B
(es)
|
2008-05-21 |
2018-01-08 |
Ariad Pharma Inc |
Derivados fosforosos como inhibidores de cinasa.
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
NZ603525A
(en)
|
2008-06-27 |
2015-02-27 |
Celgene Avilomics Res Inc |
Pyrimidine based compound and uses thereof
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US9908884B2
(en)
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
|
US8367689B2
(en)
*
|
2009-05-06 |
2013-02-05 |
Portola Pharmaceuticals, Inc. |
Inhibitors of JAK
|
|
EP2440204B1
(en)
|
2009-06-12 |
2013-12-18 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
|
US9556426B2
(en)
|
2009-09-16 |
2017-01-31 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
|
US8466155B2
(en)
*
|
2009-10-02 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Pyrimidines
|
|
JP2013516422A
(ja)
|
2009-12-30 |
2013-05-13 |
アビラ セラピューティクス， インコーポレイテッド |
タンパク質のリガンド−指向性共有的修飾
|
|
US9290499B2
(en)
|
2010-05-19 |
2016-03-22 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
US8927547B2
(en)
|
2010-05-21 |
2015-01-06 |
Noviga Research Ab |
Pyrimidine derivatives
|
|
ES2577829T3
(es)
|
2010-06-04 |
2016-07-19 |
F. Hoffmann-La Roche Ag |
Derivados de aminopirimidina como moduladores de la LRRK2
|
|
MX336875B
(es)
|
2010-08-10 |
2016-02-04 |
Celgene Avilomics Res Inc |
Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
|
|
EP2635284B1
(en)
|
2010-11-01 |
2019-12-18 |
Celgene CAR LLC |
Heterocyclic compounds and uses thereof
|
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
|
WO2012064706A1
(en)
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
|
NO2638031T3
(enExample)
|
2010-11-10 |
2018-03-10 |
|
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
DK2688883T3
(en)
|
2011-03-24 |
2016-09-05 |
Noviga Res Ab |
pyrimidine
|
|
JP6147727B2
(ja)
*
|
2011-04-01 |
2017-06-14 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
|
|
ES2759615T3
(es)
|
2011-04-01 |
2020-05-11 |
Univ Utah Res Found |
Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
|
|
US9139534B2
(en)
|
2011-04-22 |
2015-09-22 |
Signal Pharmaceuticals, Llc |
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
|
|
PL2701510T3
(pl)
|
2011-04-25 |
2017-07-31 |
Usher Iii Initiative Inc |
Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera
|
|
EP2704572B1
(en)
|
2011-05-04 |
2015-12-30 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
EP4119551A1
(en)
|
2011-07-27 |
2023-01-18 |
Astrazeneca AB |
2-(2,4,5-substituted-anilino)pyrimidine compounds
|
|
MX2014004086A
(es)
|
2011-10-03 |
2014-09-22 |
Univ North Carolina |
Compuestos de pirrolopirimidina para el tratamiento del cancer.
|
|
US9364476B2
(en)
|
2011-10-28 |
2016-06-14 |
Celgene Avilomics Research, Inc. |
Methods of treating a Bruton's Tyrosine Kinase disease or disorder
|
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
|
WO2013106792A1
(en)
|
2012-01-13 |
2013-07-18 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses as anticancer agents.
|
|
US9464089B2
(en)
*
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
|
EA026353B1
(ru)
|
2012-01-17 |
2017-03-31 |
Астеллас Фарма Инк. |
Соединение пиразинкарбоксамида
|
|
CA2866852C
(en)
*
|
2012-03-15 |
2020-12-29 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
|
BR112014022790B1
(pt)
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
|
|
WO2013169401A1
(en)
*
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
WO2013173518A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
AU2013266438B2
(en)
*
|
2012-05-22 |
2017-09-07 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
WO2014039452A1
(en)
*
|
2012-09-04 |
2014-03-13 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
WO2014055928A2
(en)
|
2012-10-04 |
2014-04-10 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
CA2887465A1
(en)
|
2012-10-04 |
2014-04-10 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
EP2909211A4
(en)
|
2012-10-17 |
2016-06-22 |
Univ North Carolina |
PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
|
|
US9227976B2
(en)
|
2012-10-25 |
2016-01-05 |
Usher Iii Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
|
US8765762B2
(en)
|
2012-10-25 |
2014-07-01 |
Usher III, Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
|
|
WO2014081714A2
(en)
*
|
2012-11-20 |
2014-05-30 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
WO2014081709A2
(en)
*
|
2012-11-20 |
2014-05-30 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
WO2014081712A2
(en)
*
|
2012-11-20 |
2014-05-30 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
US20140142128A1
(en)
*
|
2012-11-20 |
2014-05-22 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
EP2925752A4
(en)
|
2012-11-27 |
2016-06-01 |
Univ North Carolina |
PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9126950B2
(en)
*
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
JP2016506930A
(ja)
|
2013-01-25 |
2016-03-07 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
炎症性腸疾患を処置するための化合物および方法
|
|
MX2015009952A
(es)
|
2013-02-08 |
2015-10-05 |
Celgene Avilomics Res Inc |
Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
|
|
US20140357636A1
(en)
*
|
2013-02-21 |
2014-12-04 |
Wayne Rothbaum |
Treatment of Skeletal-Related Disorders
|
|
AR094929A1
(es)
|
2013-02-28 |
2015-09-09 |
Bristol Myers Squibb Co |
Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
|
|
CN105102448B
(zh)
|
2013-02-28 |
2018-03-06 |
百时美施贵宝公司 |
作为rock1和rock2抑制剂的苯基吡唑衍生物
|
|
WO2014140582A1
(en)
|
2013-03-14 |
2014-09-18 |
Respivert Limited |
Kinase inhibitors
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA2902686C
(en)
|
2013-04-25 |
2017-01-24 |
Beigene, Ltd. |
Fused heterocyclic compounds as protein kinase inhibitors
|
|
EP2994456A4
(en)
*
|
2013-05-06 |
2017-01-04 |
Clovis Oncology, Inc. |
Salts of an epidermal growth factor receptor kinase inhibitor
|
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
|
WO2014210255A1
(en)
|
2013-06-26 |
2014-12-31 |
Abbvie Inc. |
Primary carboxamides as btk inhibitors
|
|
CN105377835B
(zh)
*
|
2013-07-11 |
2018-08-17 |
贝达药业股份有限公司 |
酪氨酸蛋白激酶调节剂及其应用方法
|
|
KR102173433B1
(ko)
*
|
2013-07-11 |
2020-11-04 |
에이시아 바이오사이언시스 인코포레이티드. |
키나아제 억제제로써의 피리미딘 유도체
|
|
MX360498B
(es)
|
2013-08-12 |
2018-11-05 |
Taiho Pharmaceutical Co Ltd |
Compuesto novedoso de pirimidina fusionada o sal del mismo.
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
WO2015039613A1
(zh)
*
|
2013-09-18 |
2015-03-26 |
北京韩美药品有限公司 |
抑制btk和/或jak3激酶活性的化合物
|
|
BR112016008632A8
(pt)
|
2013-10-21 |
2020-03-17 |
Merck Patent Gmbh |
compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
|
|
JP2016538270A
(ja)
|
2013-10-25 |
2016-12-08 |
ファーマサイクリックス エルエルシー |
移植片対宿主病を処置し予防する方法
|
|
US9415049B2
(en)
*
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
NZ715903A
(en)
|
2014-01-30 |
2017-06-30 |
Signal Pharm Llc |
Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
|
|
US9622483B2
(en)
|
2014-02-19 |
2017-04-18 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US11039620B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US11039621B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
CN104860941B
(zh)
*
|
2014-02-25 |
2017-03-22 |
上海海雁医药科技有限公司 |
2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
|
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2015134805A1
(en)
*
|
2014-03-07 |
2015-09-11 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
US9555031B2
(en)
|
2014-04-11 |
2017-01-31 |
The University Of North Carolina At Chapel Hill |
Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
|
|
EP3144292B1
(en)
|
2014-04-14 |
2020-08-26 |
Shanghai Haiyan Pharmaceutical Technology Co., Ltd |
2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
|
|
EP3131550B1
(en)
*
|
2014-04-16 |
2021-05-26 |
Signal Pharmaceuticals, LLC |
Methods for treating cancer using tor kinase inhibitor combination therapy with a histone deacetylase inhibitor
|
|
US10300058B2
(en)
|
2014-04-18 |
2019-05-28 |
Xuanzhu Pharma Co., Ltd. |
Tyrosine kinase inhibitor and uses thereof
|
|
CN104130265B
(zh)
*
|
2014-04-29 |
2017-01-25 |
苏州景泓生物技术有限公司 |
一种含有螺环或桥环的嘧啶类化合物
|
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
CN105315285B
(zh)
*
|
2014-07-25 |
2017-12-08 |
上海海雁医药科技有限公司 |
2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
|
|
CR20170077A
(es)
|
2014-08-04 |
2017-06-26 |
Nuevolution As |
Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
|
|
CN117088931A
(zh)
|
2014-08-12 |
2023-11-21 |
莫纳什大学 |
定向淋巴的前药
|
|
EP3179858B1
(en)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Forms and compositions of an erk inhibitor
|
|
US10266549B2
(en)
*
|
2014-08-25 |
2019-04-23 |
Salk Institute For Biological Studies |
ULK1 inhibitors and methods using same
|
|
CN105399685B
(zh)
*
|
2014-09-16 |
2018-05-22 |
深圳微芯生物科技有限责任公司 |
作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用
|
|
CN105399686B
(zh)
*
|
2014-09-16 |
2018-05-22 |
深圳微芯生物科技有限责任公司 |
嘧啶衍生物、其制备方法及其应用
|
|
CN105481778B
(zh)
*
|
2014-09-16 |
2019-06-04 |
深圳微芯生物科技股份有限公司 |
嘧啶衍生物、其制备方法及其应用
|
|
RS62017B1
(sr)
|
2014-09-17 |
2021-07-30 |
Celgene Car Llc |
Mk2 inhibitori i njihova upotreba
|
|
WO2016054987A1
(zh)
*
|
2014-10-11 |
2016-04-14 |
上海翰森生物医药科技有限公司 |
Egfr抑制剂及其制备和应用
|
|
WO2016060963A1
(en)
|
2014-10-14 |
2016-04-21 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CN107148425B
(zh)
|
2014-10-29 |
2021-08-03 |
拜斯科阿迪有限公司 |
对mt1-mmp特异性的双环肽配体
|
|
CN105601573B
(zh)
*
|
2014-11-24 |
2021-07-02 |
中国科学院上海药物研究所 |
2-氨基嘧啶类化合物及其药物组合物和应用
|
|
AU2015360547A1
(en)
*
|
2014-12-11 |
2017-06-01 |
Merck Patent Gmbh |
Assays for BTK inhibitors
|
|
CN107108524A
(zh)
|
2014-12-16 |
2017-08-29 |
西格诺药品有限公司 |
2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物
|
|
US9513297B2
(en)
|
2014-12-16 |
2016-12-06 |
Signal Pharmaceuticals, Llc |
Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
|
|
EP3250557B1
(en)
|
2015-01-29 |
2024-11-20 |
Signal Pharmaceuticals, LLC |
Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
|
|
TR201910158T4
(tr)
*
|
2015-01-30 |
2019-07-22 |
Taiho Pharmaceutical Co Ltd |
İmmün hastalıklara yönelik önleyici ve/veya terapötik ajan.
|
|
CN107207517B
(zh)
|
2015-01-30 |
2019-06-07 |
大鹏药品工业株式会社 |
稠合嘧啶化合物的盐及其结晶
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
TWI788655B
(zh)
|
2015-02-27 |
2023-01-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
ES2854703T3
(es)
*
|
2015-07-09 |
2021-09-22 |
Merck Patent Gmbh |
Compuestos de heteroarilo como inhibidores de BTK y usos de los mismos
|
|
CN107922287B
(zh)
|
2015-07-24 |
2021-04-09 |
细胞基因公司 |
合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
|
|
MA45973A
(fr)
|
2015-08-31 |
2019-06-26 |
Pharmacyclics Llc |
Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
|
|
TWI707852B
(zh)
|
2015-09-02 |
2020-10-21 |
美商林伯士拉克許米公司 |
Tyk2 抑制劑及其用途
|
|
US11738087B2
(en)
|
2015-09-08 |
2023-08-29 |
Monash University |
Lymph directing prodrugs
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
JP7337502B2
(ja)
|
2015-09-16 |
2023-09-04 |
ロクソ オンコロジー， インコーポレイテッド |
がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
|
|
CN106554347B
(zh)
*
|
2015-09-25 |
2020-10-30 |
浙江博生医药有限公司 |
Egfr激酶抑制剂及其制备方法和应用
|
|
JP6889494B2
(ja)
|
2015-10-09 |
2021-06-18 |
エイシア セラピューティクス， インコーポレイテッド |
ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法
|
|
HUE068392T2
(hu)
*
|
2015-10-21 |
2024-12-28 |
Otsuka Pharma Co Ltd |
Benzolaktám vegyületek mint fehérje kináz gátlók
|
|
AU2016342027B2
(en)
|
2015-10-23 |
2021-05-13 |
Navitor Pharmaceuticals, Inc. |
Modulators of Sestrin-GATOR2 interaction and uses thereof
|
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
|
|
CN114716381B
(zh)
|
2015-12-16 |
2025-03-11 |
洛克索肿瘤学股份有限公司 |
可用作激酶抑制剂的化合物
|
|
CN107021963A
(zh)
|
2016-01-29 |
2017-08-08 |
北京诺诚健华医药科技有限公司 |
吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
|
|
DK3426243T3
(da)
|
2016-03-09 |
2021-07-19 |
Raze Therapeutics Inc |
3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
|
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
US10709708B2
(en)
|
2016-03-17 |
2020-07-14 |
The University Of North Carolina At Chapel Hill |
Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
|
|
CA3019394A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
CN105968056A
(zh)
*
|
2016-05-28 |
2016-09-28 |
大连医科大学 |
二芳基嘧啶类化合物，组合物及用途
|
|
CN109640988A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
|
US10864203B2
(en)
|
2016-07-05 |
2020-12-15 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
|
WO2018033853A2
(en)
|
2016-08-16 |
2018-02-22 |
Beigene, Ltd. |
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
WO2018033135A1
(en)
|
2016-08-19 |
2018-02-22 |
Beigene, Ltd. |
Use of a combination comprising a btk inhibitor for treating cancers
|
|
CN106316886A
(zh)
*
|
2016-08-24 |
2017-01-11 |
泰州精英化成医药科技有限公司 |
顺式‑3‑（叔丁氧羰基氨基）环己烷甲酸的制备方法
|
|
IL292938A
(en)
|
2016-09-19 |
2022-07-01 |
Mei Pharma Inc |
Combined treatment
|
|
US10323036B2
(en)
|
2016-10-14 |
2019-06-18 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
CN107973754B
(zh)
*
|
2016-10-25 |
2020-04-14 |
清华大学 |
一种小分子抑制剂及其制备方法与其在多发性骨髓瘤治疗中的应用
|
|
JP2020023441A
(ja)
*
|
2016-11-02 |
2020-02-13 |
国立大学法人九州大学 |
Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物
|
|
JP2019532997A
(ja)
|
2016-11-03 |
2019-11-14 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法とｂｔｋ阻害剤との併用療法
|
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
|
CA3043768A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
WO2018115203A1
(en)
|
2016-12-23 |
2018-06-28 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
|
CN106632273A
(zh)
*
|
2016-12-29 |
2017-05-10 |
大连医科大学 |
含唑杂环的嘧啶类化合物，组合物及其用途
|
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
CN108329274B
(zh)
*
|
2017-01-13 |
2021-09-03 |
正大天晴药业集团股份有限公司 |
布鲁顿酪氨酸激酶抑制剂
|
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
CN108498477A
(zh)
*
|
2017-02-27 |
2018-09-07 |
江苏奥赛康药业股份有限公司 |
一种2-氨基嘧啶类化合物的药用组合物及其制备方法
|
|
TW202515876A
(zh)
|
2017-03-08 |
2025-04-16 |
日商武田藥品工業股份有限公司 |
Tyk2抑制劑及其用途
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
AU2017408099A1
(en)
|
2017-04-07 |
2019-11-07 |
ACEA Therapeutics, Inc. |
Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
|
|
IL269933B
(en)
|
2017-04-14 |
2022-07-01 |
Biogen Ma Inc |
Benzozapine analogues as inhibitors for proton tyrosine kinase
|
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
TWI787284B
(zh)
|
2017-06-22 |
2022-12-21 |
美商西建公司 |
以b型肝炎病毒感染表徵之肝細胞癌之治療
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
EP3645549A1
(en)
|
2017-06-26 |
2020-05-06 |
BicycleRD Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
|
SI3658557T1
(sl)
|
2017-07-28 |
2024-10-30 |
Takeda Pharmaceutical Company Limited |
Zaviralci TYK2 in njihova uporaba
|
|
JP7670481B2
(ja)
|
2017-08-04 |
2025-04-30 |
バイスクルテクス・リミテッド |
Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
|
|
US11377449B2
(en)
|
2017-08-12 |
2022-07-05 |
Beigene, Ltd. |
BTK inhibitors with improved dual selectivity
|
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
JP2020531574A
(ja)
*
|
2017-08-18 |
2020-11-05 |
北京韓美薬品有限公司Ｂｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍ． Ｃｏ．， Ｌｔｄ． |
化合物、その医薬組成物及びその使用及び応用
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
CA3077739A1
(en)
|
2017-08-29 |
2019-03-07 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
KR102383561B1
(ko)
*
|
2017-09-07 |
2022-04-06 |
한국화학연구원 |
테트라히드로이소퀴놀린기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
EP3707138B1
(en)
|
2017-11-06 |
2022-07-13 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
JP7229257B2
(ja)
|
2018-01-29 |
2023-02-28 |
メルク パテント ゲーエムベーハー |
Ｇｃｎ２阻害剤およびその使用
|
|
BR112020015396A2
(pt)
|
2018-01-29 |
2020-12-08 |
Merck Patent Gmbh |
Inididores de gcn2 e usos dos mesmos
|
|
TWI798334B
(zh)
|
2018-01-31 |
2023-04-11 |
大陸商迪哲（江蘇）醫藥股份有限公司 |
Ｅｒｂｂ／ｂｔｋ抑制劑
|
|
CN111902429A
(zh)
|
2018-02-23 |
2020-11-06 |
拜斯科技术开发有限公司 |
多聚体双环肽配体
|
|
EP3759086A1
(en)
|
2018-02-27 |
2021-01-06 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of tcr-nck interaction
|
|
KR20210003780A
(ko)
|
2018-04-05 |
2021-01-12 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Axl 키나제 억제제 및 그의 용도
|
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
|
HRP20241163T1
(hr)
|
2018-04-24 |
2024-11-22 |
Merck Patent Gmbh |
Antiproliferacijski spojevi i njihova uporaba
|
|
GEP20227433B
(en)
|
2018-04-26 |
2022-10-25 |
Pfizer |
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
|
|
KR20210044736A
(ko)
|
2018-05-03 |
2021-04-23 |
주노 쎄러퓨티크스 인코퍼레이티드 |
키메라 항원 수용체(ｃａｒ) ｔ세포 요법과 키나제 억제제의 조합요법
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
WO2019241789A1
(en)
|
2018-06-15 |
2019-12-19 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
WO2020051424A1
(en)
|
2018-09-07 |
2020-03-12 |
Pic Therapeutics |
Eif4e inhibitors and uses thereof
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
CN113271940A
(zh)
|
2018-10-15 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
CN109608444B
(zh)
*
|
2018-11-27 |
2022-02-11 |
中国药科大学 |
含异吲哚啉酮的erk抑制剂及其制备方法与用途
|
|
CA3120866A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
US12492224B2
(en)
|
2018-12-21 |
2025-12-09 |
Bicycletx Limited |
Bicyclic peptide ligands specific for PD-L1
|
|
WO2020128527A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
CN113348021B
(zh)
|
2019-01-23 |
2025-07-11 |
武田药品工业株式会社 |
Tyk2抑制剂和其用途
|
|
CN109776495A
(zh)
*
|
2019-01-31 |
2019-05-21 |
李佳睿 |
抗肿瘤化合物及其制备方法与用途
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
CA3133766A1
(en)
|
2019-03-29 |
2020-10-08 |
Astrazeneca Ab |
Osimertinib for use in the treatment of non-small cell lung cancer
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
SG11202110828UA
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Ltd |
Bicycle toxin conjugates and uses thereof
|
|
CN120574283A
(zh)
|
2019-04-05 |
2025-09-02 |
凯麦拉医疗公司 |
Stat降解剂和其用途
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
PE20220597A1
(es)
|
2019-05-10 |
2022-04-22 |
Deciphera Pharmaceuticals Llc |
Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
|
|
US11518758B2
(en)
|
2019-05-10 |
2022-12-06 |
Deciphera Pharmaceuticals, Llc |
Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
CA3141826A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
US20220249491A1
(en)
|
2019-06-10 |
2022-08-11 |
Beigene Switzerland Gmbh |
Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
|
|
PE20221083A1
(es)
|
2019-06-17 |
2022-07-05 |
Deciphera Pharmaceuticals Llc |
Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
|
|
WO2020257495A1
(en)
*
|
2019-06-18 |
2020-12-24 |
Purdue Research Foundation |
Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CN110305140B
(zh)
*
|
2019-07-30 |
2020-08-04 |
上海勋和医药科技有限公司 |
二氢吡咯并嘧啶类选择性jak2抑制剂
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
CA3150681A1
(en)
|
2019-08-14 |
2021-02-18 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
US11845724B2
(en)
|
2019-09-11 |
2023-12-19 |
Vincere Biosciences, Inc. |
USP30 inhibitors and uses thereof
|
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
|
CN112574207B
(zh)
*
|
2019-09-30 |
2023-04-11 |
南京药石科技股份有限公司 |
Erk1/2蛋白激酶抑制剂及其用途
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11851426B2
(en)
|
2019-10-11 |
2023-12-26 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN112773802B
(zh)
*
|
2019-11-08 |
2023-11-21 |
深圳微芯生物科技股份有限公司 |
一种化合物用于预防或治疗移植物抗宿主病的用途
|
|
CA3162886A1
(en)
*
|
2019-11-26 |
2021-06-03 |
Shenzhen Chipscreen Biosciences Co., Ltd. |
Composition containing aromatic heterocyclic compound in amorphous form, and preparation method therefor and use thereof
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
AU2020397938A1
(en)
|
2019-12-05 |
2022-06-23 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and uses thereof
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
UY38994A
(es)
|
2019-12-20 |
2021-07-30 |
Nuevolution As |
Compuestos activos frente a receptores nucleares
|
|
MX2022007265A
(es)
|
2019-12-20 |
2022-09-09 |
Nuevolution As |
Compuestos activos frente a receptores nucleares.
|
|
EP4081308A4
(en)
|
2019-12-23 |
2024-01-24 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
US12441707B2
(en)
|
2019-12-30 |
2025-10-14 |
Tyra Biosciences, Inc. |
Indazole compounds
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN111620852B
(zh)
*
|
2020-01-19 |
2023-05-09 |
镇江植生源农业科技有限公司 |
一种5-氯-嘧啶-2,4-二胺类化合物及其制备方法和应用
|
|
IL295362A
(en)
|
2020-02-05 |
2022-10-01 |
Puretech Lyt Inc |
Lipid drug inhibitors of neurosteroids
|
|
KR20220153582A
(ko)
|
2020-02-14 |
2022-11-18 |
솔크 인스티튜트 포 바이올로지칼 스터디즈 |
마크로시클릭 ulk1/2 억제제
|
|
TW202146393A
(zh)
|
2020-03-03 |
2021-12-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
|
KR20230005160A
(ko)
|
2020-03-19 |
2023-01-09 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Mdm2 분해제 및 이의 용도
|
|
AU2021245397A1
(en)
|
2020-03-31 |
2022-10-20 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
WO2021198956A1
(en)
|
2020-03-31 |
2021-10-07 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
CN115697985B
(zh)
|
2020-04-07 |
2025-01-21 |
米托布里奇公司 |
Cd38抑制剂
|
|
US20230250110A1
(en)
|
2020-06-03 |
2023-08-10 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CN111646978B
(zh)
*
|
2020-06-11 |
2021-12-21 |
浙江大学 |
N2-取代烷氧芳环-2-氨基嘧啶类衍生物及应用
|
|
WO2022006518A1
(en)
*
|
2020-07-02 |
2022-01-06 |
The Cleveland Clinic Foundation |
Compounds and methods of promoting oligodendrocyte precursor differentiation
|
|
EP4178580B1
(en)
|
2020-07-09 |
2025-11-05 |
Usher III Initiative, Inc. |
Bf 844 for use in the treatment of cancer
|
|
AU2021322934A1
(en)
|
2020-08-03 |
2023-03-30 |
Bicycletx Limited |
Peptide-based linkers
|
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
TW202212331A
(zh)
*
|
2020-09-22 |
2022-04-01 |
英屬開曼群島商百濟神州有限公司 |
作為ｅｇｆｒ抑製劑之吲哚啉化合物及衍生物
|
|
WO2022072632A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Scorpion Therapeutics, Inc. |
Bicyclic compounds for use in the treatment cancer
|
|
US12331046B2
(en)
|
2020-10-23 |
2025-06-17 |
Nimbus Clotho, Inc. |
CTPS1 inhibitors and uses thereof
|
|
CA3200814A1
(en)
|
2020-12-02 |
2022-06-09 |
Alfredo C. Castro |
Tead inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
US12378229B2
(en)
|
2021-02-02 |
2025-08-05 |
Liminal Biosciences Limited |
GPR84 antagonists and uses thereof
|
|
MX2023009060A
(es)
|
2021-02-02 |
2023-09-29 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
EP4291235A4
(en)
|
2021-02-12 |
2025-01-08 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
US12171768B2
(en)
|
2021-02-15 |
2024-12-24 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
CN115160319B
(zh)
*
|
2021-04-01 |
2023-12-26 |
西安新通药物研究股份有限公司 |
含1,3-苯并二氧戊环结构的化合物及其制备方法与用途
|
|
EP4313023A1
(en)
|
2021-04-02 |
2024-02-07 |
Biogen MA Inc. |
Combination treatment methods of multiple sclerosis
|
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
KR20240020735A
(ko)
|
2021-05-07 |
2024-02-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Cdk2 분해제 및 그 용도
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
CA3229560A1
(en)
|
2021-08-25 |
2023-03-02 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
US12233056B2
(en)
|
2022-04-06 |
2025-02-25 |
Syntara Limited |
Lysyl oxidase inhibitors for treating myeloid malignancies
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
|
US20260028330A1
(en)
|
2022-08-02 |
2026-01-29 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
IL318577A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
|
|
KR20250056924A
(ko)
|
2022-08-02 |
2025-04-28 |
리미널 바이오사이언시스 리미티드 |
치환된 피리돈 gpr84 길항제 및 이의 용도
|
|
CN115448906B
(zh)
*
|
2022-09-26 |
2024-04-02 |
深圳大学 |
一种2-苯胺基嘧啶类衍生物及其制备方法与应用
|
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
AU2024312190A1
(en)
|
2023-06-23 |
2025-07-03 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
AU2024344754A1
(en)
|
2023-09-21 |
2026-04-02 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|
|
WO2025061148A1
(zh)
*
|
2023-09-22 |
2025-03-27 |
江苏恒瑞医药股份有限公司 |
杂芳基类化合物、其制备方法及其在医药上的应用
|
|
CN119707835A
(zh)
*
|
2024-11-25 |
2025-03-28 |
沈阳药科大学 |
2-氨基嘧啶-5-甲酰胺类化合物及用于制备治疗和/或预防癌症药物中的用途
|